PKX vs IONS Comparison

POSCO Holdings Inc is a holding company and operates through its subsidiaries. The company operates across four distinct segments. The first segment is the Steel Segment, which includes the production and sale of steel products. The second segment is the Infrastructure Business, which is further divided into three operations. The Trading Segment comprises trading and natural resource development activities. The Construction Segment involves the planning, designing, and construction of industrial plants, civil engineering projects, and buildings. The Logistics and Others Segment. The third segment is the Secondary Battery Materials Segment, and the fourth segment is the Others Segment.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.